Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011

Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2011', provides an overview of the Islet Cell Carcinoma (Insulinoma) therapeutic pipeline. This report provides information on the therapeutic development for Islet Cell Carcinoma (Insulinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Islet Cell Carcinoma (Insulinoma). 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Islet Cell Carcinoma (Insulinoma).
• A review of the Islet Cell Carcinoma (Insulinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Islet Cell Carcinoma (Insulinoma) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Islet Cell Carcinoma (Insulinoma).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Islet Cell Carcinoma (Insulinoma) pipeline depth and focus of Islet Cell Carcinoma (Insulinoma) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Islet Cell Carcinoma (Insulinoma) Overview
Therapeutics Development
An Overview of Pipeline Products for Islet Cell Carcinoma (Insulinoma)
Islet Cell Carcinoma (Insulinoma) Therapeutics under Development by Companies
Islet Cell Carcinoma (Insulinoma) Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Islet Cell Carcinoma (Insulinoma) Therapeutics – Products under Development by Companies
Islet Cell Carcinoma (Insulinoma) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Islet Cell Carcinoma (Insulinoma) Therapeutics Development
Novartis AG
ImClone Systems Incorporated
ImmunoGen, Inc.
Threshold Pharmaceuticals, Inc.
Virobay Inc.
Islet Cell Carcinoma (Insulinoma) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMGN901 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
VBY-825 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sorafenib + RAD001 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Bevacizumab + Temozolomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AMG 706 + Octreotide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Temsirolimus + Bevacizumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AMG 479 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Thalidomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ZD1839 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lithium Carbonate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
FOLFIRI - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sutent - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sorafenib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Paclitaxel + Carboplatin + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Thalidomide + Temodar - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
IMC-A12 + Octreotide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
TH-302 + Sunitinib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Bevacizumab + Pertuzumab + Sandostatin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fluouracil + Octreotide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SOM230 LAR + RAD001 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Temozolomide + Pazopanib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Islet Cell Carcinoma (Insulinoma) Therapeutics – Drug Profile Updates
Islet Cell Carcinoma (Insulinoma) – Product Development Milestones
Islet Cell Carcinoma (Insulinoma) – Product Development Milestones
Featured News & Press Releases
Jul 22, 2011: Novartis Drug Afinitor Recommended By CHMP For EU Approval To Treat Patients With Advanced Pancreatic Neuroendocrine Tumors
May 20, 2011: SUTENT Receives FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
May 05, 2011: Novartis's Afinitor Gains FDA Approval As First New Treatment For Patients With Advanced Pancreatic Neuroendocrine Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Islet Cell Carcinoma (Insulinoma), H2 2011
Products under Development for Islet Cell Carcinoma (Insulinoma) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Novartis AG, H2 2011
ImClone Systems Incorporated, H2 2011
ImmunoGen, Inc., H2 2011
Threshold Pharmaceuticals, Inc., H2 2011
Virobay Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Islet Cell Carcinoma (Insulinoma) Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Islet Cell Carcinoma (Insulinoma), H2 2011
Products under Development for Islet Cell Carcinoma (Insulinoma) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top